INTRODUCTION AND OBJECTIVES: Data on the oncologic outcomes of high-risk prostate cancer (HRPCa) patients at 20 years after radical prostatectomy (RP) are lacking. The aim of our investigation was to evaluate the long-term patterns of biochemical (BCR), clinical recurrence (CR), cancer specific mortality (CSM) and othercause mortality (OCM) in a multi-institutional database of surgicallytreated HRPCa patients.
INTRODUCTION AND OBJECTIVES:
To estimate the conditional probability of biochemical recurrence (BCR) free survival and cancer-specific mortality (CSM) for men with clinically localized prostate cancer (PCa) treated with radical prostatectomy (RP).
METHODS: The study population consisted of 3576 consecutive patients who underwent laparoscopic radical prostatectomy (LARP) and 2619 men treated with robotic radical prostatectomy (RARP) in the last 15 years at our institution. BCR was defined as PSA0.2 ng/dl. PCa death was defined as patients who died with metastasis in an androgen independent setting. Kaplan Meier and Cox regression methods was used to estimate BCR and CSM conditional probabilities. RESULTS: Median follow-up was 8.49 years (IQR 4.01-12.97). Positive surgical margins (PSM) were identified in 1202 patients (19.4%); of these, 664 (55.24%) had organ confined disease and 523 (43.51%) had extraprostatic extension (EPE). BCR-free survival rate was significantly higher with RARP (83% vs 77% for laparoscopic surgery at 10 years; p<0.001). Patients with PSA<10 ng/dl BCR-free survival at 10 years was 80% vs 64% for PSA 10-20 ng/dl, and 59% for PSA >20ng/dl; p>0.001. Negative margins, Gleason6 and no extracapsular extension in the specimen were found to have higher BCR-free survival (all p< 0.001). Conditional probability of BCR after surgery 1st year is 6.7%. Those who reach the 2nd year without recurrence have a relapse probability of 4%, (cumulative probability 9.8%) That probability falls to 3.5% after the 3rd year (cumulative probability 13%), 2% after the 4th year (cumulative probability 15%) and is 2.1% after the 5th year (cumulative probability 17%). After 10 years of follow-up without recurrence, the subsequent probability of relapse is 0.8%, (cumulative probability 21%). A total of 92 (1.48%) patients died of disease. Among patients with BCR, those who recur within the first three years of follow-up had higher CSM (9% vs 4% for BCR after 3 years; p¼0.04). The table shows the variables associated with CSM in multivariable analysis.
CONCLUSIONS: We found a 50% decrease in BCR probability in patients who had not recurred with the first 3 years. Similar drop was identified for CSM. This is not only useful for patients counseling but also to optimize postoperative follow-up strategies. 
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INTRODUCTION AND OBJECTIVES:
We aimed to assess the risk of cancer-specific mortality (CSM) in patients with PSA persistence after radical prostatectomy (RP) after accounting for other-cause mortality (OCM). We hypothesized that a non-negligible proportion of patients is at risk of dying from other causes and would not benefit from additional cancer therapies.
METHODS: We included 829 patients with localized PCa undergoing RP at two referral centers between 1994 and 2014. All patients had PSA persistence after RP defined as a PSA 0.1 ng/ml at 8 weeks after surgery. A graphical illustration of the 10-year CSM and OCM rates was generated using competing-risks Poisson regression analyses. Patients were stratified according to age (<65 vs. 65 years) and according to their probability of dying from PCa at 10-years (stratified as <10% vs. 10-30% vs. >30%), which was developed from a Cox regression model based on pathologic characteristics and first PSA after surgery. For each strata, survival estimates were calculated. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e987
Competing-risks regression models were used to test the effect of age and disease characteristics on CSM after accounting for OCM. RESULTS: Overall, 223 (26.9%), 331 (39.9%), and 275 (33.2%) patients had pathologic Gleason score 6, 7, and 8, and 400 (48.3%), 215 (25.9%), 214 (25.8%), and 172 (20.7%) patients had pT2, pT3a, pT3b/4, and pN1 disease. The median first PSA after surgery was 0.33 ng/ml. Median follow-up was 107 months, during which time 90 and 136 patients died from PCa and from OCM. The 10-year CSM and OCM rates were 12.6% and 11.9%. When considering men with a risk of dying from PCa <10%, the 10-year rate of OCM was higher as compared to the CSM rate (8 vs. 1.6%), regardless of age. The proportion of patients who died from OCM at 10-year was 4.2% in men <65 years with a probability of dying from PCa >30% vs. 18.2% in patients 65 years with a probability of CSM between 10 and 30%. In men with a calculated risk of dying from PCa >30% the 10-year CSM rates were 43.7 vs. 34.1% for those aged <65 vs. 65 years old. At multivariable regression analyses, the number of positive nodes, first PSA after surgery, and pathologic Gleason score 8-10 (all p<0.001) were associated with the risk of CSM after accounting for the risk of dying from other causes.
CONCLUSIONS: Up to 20% of men with PSA persistence after RP will ultimately die from other causes. Conversely, patients with Gleason score 8-10, higher PSA after surgery, and a higher number of positive nodes are at increased risk of CSM. These patients might benefit from additional cancer therapies, while men less likely to die from PCa may be spared such treatments.
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PD51-11 PATHOLOGICAL FINDINGS AT RADICAL PROSTATECTOMY AFTER INITIAL ACTIVE SURVEILLANCE IN LOW-RISK PROSTATE CANCER PATIENTS. DID WE MISS THE CHANCE TO CURE?
INTRODUCTION AND OBJECTIVES: No previous study calculated tumor volume (TV) at pathology in patients enrolled in active surveillance (AS) programs who are eventually treated with radical prostatectomy (RP). We assessed pathological characteristics in these patients as compared to those found in patients eligible for AS but chosen to undergo immediate RP.
METHODS: Between 2009 and 2016, 235 consecutive patients were enrolled into our AS program for low-risk PCa according to the PRIAS criteria. During AS, 88 (37.4%) patients were switched to active treatment because of rising PSA, pathological upgrading (Gleason>6 or >2 positive cores) or patient preference. Of these, 48 patients (55%) were submitted to RP at our center. We examined the pathological characteristics of RP in these patients. TV was calculated as prostate weight x percentage of cancer at whole mount pathology. Finally, we compared these figures with those found in the pathological examination of 274 consecutive patients who could have been considered eligible for AS at the time of diagnosis that were instead submitted to immediate RP. RESULTS: Median time from AS entry to RP (n¼48) was 14 months (IQR: 11-25.5). Median TV in patients treated with RP after AS was 3.4 ml vs. 2.07 ml in immediate RP patients (p¼0.002). In patients who progressed during AS and then received RP (n¼48), 38 (79.2%), 11 (22.9%), 2 (4.2%), and 3 (6.3%) had Gleason score >6, extracapsular extension (ECE), seminal vesicles invasion (SVI) and nodal invasion (LNI), respectively. In patients submitted to immediate RP, 85 (30.9%), 13 (4.7%), 1 (0.4%) and 0 (0%) had Gleason score >6, ECE, SVI and LNI, respectively. Patients initially managed with AS had higher rates of Gleason >6 (7.7% vs. 35.4%), ECE (22.9 vs. 4.7%), SVI (4.2 vs. 0.4%), LNI (6.3 vs. 0%) and higher (all p<0.001). However, when the rates of adverse pathology of patients who progressed during AS (n¼48) were recalculated on the total number of patients who entered the AS program (n¼235), these figures were virtually identical to those of patients submitted to immediate RP (all p: n.s.), suggesting that time on AS did not worsen pathological outcomes.
CONCLUSIONS: Patients initially managed with AS seem to show higher rates of adverse pathology compared to similar patients treated with immediate RP. However, when applied to the overall population of AS patients, the rate of upstaging and upgrading at diagnosis remained stable during AS. The findings of adverse pathology at RP seem to be more related to initial misclassification instead of real clinical progression.
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